---

The mechanism most buyers have never heard of

Under a normal detention, FDA examines samples before deciding whether to release a shipment. Under Detention Without Physical Examination - DWPE - the agency has already concluded it has enough prior evidence of a violation that examination is unnecessary. The shipment is held on arrival, automatically, because of where it came from.

FDA maintains well over a hundred active import alerts at any given moment, covering firms in more than eighty countries. Being added is not a warning shot. It is an operational change: every future entry from that establishment clears customs through an automated flag, with no inspector needing to look at anything.

Getting removed is not simple either. The owner or consignee has to provide documentation to the FDA division compliance office demonstrating that the underlying violations have been adequately corrected, and CDER reviews it. Removing a foreign establishment from the Red List entirely requires showing the agency that the conditions which produced the appearance of a violation have been resolved. That is a compliance project measured in months, not a phone call.

None of this appears on a vendor's website. A facility can be under DWPE while the products it made are already sitting in a warehouse in the United States, listed for sale, purity figure and all.

The three alerts sitting over this category

Import Alert 66-40 - Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs.

This is the manufacturing-quality alert, and it is the one that matters most for research materials. FDA conducts foreign inspections and remote regulatory assessments of pharmaceutical establishments that manufacture, process, pack or hold drugs intended for sale in the US. When an inspection - FDA's own, a remote assessment, or one conducted by a foreign authority under a memorandum of understanding - shows an establishment is not operating in conformity with current good manufacturing practice, DWPE becomes available. CDER or CVM evaluates each case individually.

Note what triggers this alert. Not a bad batch. Not a failed sample. The facility's systems. A firm lands here because how it manufactures was found deficient, which means every product it makes is implicated, including the ones that happened to test fine.

Import Alert 66-41 - Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.

Revised most recently in May 2026. FDA's stated rationale is straightforward: unapproved new drugs carry public health risk because nobody has reviewed them for safety or effectiveness. Without that review, there is no way to know whether a drug is safe and effective for its intended use, whether it was manufactured in a way that produces consistent quality, or whether its labeling is complete and accurate.

That middle clause is the one to sit with. FDA is naming manufacturing consistency as a distinct unknown, separate from safety and separate from labeling. It is exactly the gap that documentation is supposed to close - and exactly the gap that a purity number with no verifiable lab behind it does not close.

Import Alert 66-80 - Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances.

Published March 2026, and peptide-specific. FDA's reasoning: it has approved several GLP-1 receptor agonist products for type 2 diabetes and chronic weight management, and it is aware that some patients and healthcare professionals may seek out unapproved GLP-1 products containing ingredients like semaglutide and tirzepatide.

The category most responsible for peptides entering mainstream conversation is the category with its own dedicated import alert on bulk substance.

One more detail worth knowing about all three: commercial and promotional shipments, and products subject to DWPE generally, are not amenable to enforcement discretion - including the personal importation policy people sometimes assume covers small quantities.

What this means if you are buying research material

Here is the uncomfortable part. If your supplier imports its API, you are exposed to a supply chain you cannot see, evaluated by an agency whose findings you will never be shown.

Consider what you actually have access to when you evaluate a vendor. A product page. A purity figure. Possibly a certificate of analysis. What you do not have is the name of the facility that synthesized the compound, that facility's inspection history, whether it has been the subject of a remote regulatory assessment, or whether it currently appears on a Red List.

Even a genuine COA does not answer this. A COA reports on a sample. An import alert is about the establishment - its sterility assurance, its process controls, its documentation practices, its record-keeping integrity. Those are the systems that determine whether the next lot resembles the one that was tested. A certificate tells you about the material in front of the analyst. It cannot tell you about the manufacturing system that produced it, and it certainly cannot tell you whether that system passed inspection.

This is the argument for domestic manufacturing, and it is a structural argument rather than a patriotic one. But it needs a distinction that most "made in the USA" marketing skips.

Peptide production has three stages, and they are not equivalent.

Starting materials are the inputs - protected amino acids, resins, coupling reagents. These come from a small number of specialist chemical suppliers worldwide, and a large share of that capacity sits outside the United States. Essentially every peptide manufacturer on earth, including domestic ones, including us, buys from that pool. Anyone claiming otherwise is either misinformed or counting on you not to ask.

API synthesis is where the peptide is actually built - the solid-phase chemistry, the cleavage, the purification. This is the stage that determines what the molecule is and how clean it is, and it is the stage that GMP requirements, facility inspections and import alerts are aimed at.

Fill and finish is putting the finished API into a vial and labeling it.

The meaningful question is who performs the second stage, and in what jurisdiction. A vendor that imports finished API and fills it domestically can describe itself as US-based, and the description is not false - but the chemistry that determines the product happened at a facility in a country whose inspection findings that vendor may never see, and neither will you. That is the exposure this whole post is about.

Ownership of the building is not the variable. Most peptide companies, including us, work with contract manufacturers rather than operating their own plants; that is simply how the industry is structured. What matters is where the synthesis happens and whether that facility sits inside a quality system with real oversight. A US facility is subject to US current good manufacturing practice requirements and is inspectable by FDA, and its compliance history is a matter of public record. An overseas facility may be excellent - many are - but its findings reach you, if at all, through an import alert after the fact.

BioPure's API is synthesized in the United States, at a WHO/GMP and ISO 9001 certified laboratory in California that carries the compound through to filled vial. There is no border between the synthesis and the vial, and no import chain that has to stay clear for the product to reach you. Starting materials we source the way the entire industry sources them.

We have written the fuller version of that case, including where the cost difference actually goes: why premium USA-made peptides cost more.

Five questions worth asking any supplier

None of these require a chemistry background. All of them are answerable by a supplier that knows its own supply chain.

• Where was this compound synthesized - country, and can you name the facility?
• Is the API synthesized domestically, or imported as finished API and filled here? Both get described as "made in the USA." Only one means the chemistry happened inside a US quality system.
• Which laboratory produced the certificate of analysis, and is it independent of the manufacturer?
• Is the stated purity HPLC purity or net peptide content?
• Has any facility in your supply chain been the subject of an FDA import alert?

A supplier who cannot answer the first two does not know its own supply chain, which is a complete answer in itself. A supplier who declines to answer the fifth has told you something as well.

Frequently asked questions

What does Detention Without Physical Examination mean?

It means FDA can detain a shipment on arrival without examining it, because prior findings about the facility or product already established the appearance of a violation.

Does an import alert mean a product is dangerous?

Not necessarily, and that is the point. An alert reflects a finding about an establishment's compliance - often its manufacturing systems or documentation - rather than a test result on a specific vial. A facility can be flagged for quality-system failures independent of any individual lot.

How does a facility get removed from an import alert?

By providing documentation to FDA demonstrating the violations have been adequately corrected, which CDER reviews. Full removal from the Red List requires showing the conditions that produced the violation have been resolved.

Does a Certificate of Analysis protect me from this?

A COA describes a tested sample. It does not describe the manufacturing system that produced it, and it does not reflect a facility's inspection or compliance status.

Is imported peptide API automatically a problem?

No. Import alerts name specific establishments, not entire countries. The difficulty for a buyer is that you cannot see which establishment made your material, so you cannot check.

Do domestic manufacturers use imported starting materials?

Generally yes. Protected amino acids, resins and coupling reagents come from a small pool of specialist chemical suppliers, much of it outside the US, and that is true across the industry. The distinction that matters is not where the inputs originated but where the API was synthesized, since that is the stage GMP requirements and facility inspections are aimed at.

Does it matter whether a company owns its manufacturing facility?

Less than people assume. Contract manufacturing is standard across the pharmaceutical and peptide industries, and owning a plant is not itself a quality signal. What matters is which facility does the synthesis, what quality system it operates under, and whether the vendor can name it.

Where we stand

BioPure Peptides works with a WHO/GMP and ISO 9001 certified laboratory in California that synthesizes our API and carries it through to filled vial, and we test to greater than 99% purity. Like every peptide manufacturer, we buy starting materials from the global specialist suppliers that make them - and unlike a fill-and-label operation, the chemistry that determines what is in the vial happens in the United States, inside a quality system FDA can inspect.

We will tell you where a compound was synthesized and which laboratory produced its documentation, because we know the answers and because a supplier that cannot answer those questions is asking you to trust a supply chain it has not examined itself.

Our team is in Chandler, Arizona. Call (888) 745-1505 or use our contact page, and ask us the five questions above - including the last one.

All products sold by BioPure Peptides are intended strictly for in-vitro laboratory and research use only. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease. This article is general information about a regulatory mechanism and is not legal advice.